Carr, Caitlin Son, Jessica Yao, Meng Priyadarshini, Anju Marquard, Jessica Vargas, Roberto Michener, Chad AlHilli, Mariam M
Published in
Gynecologic oncology
To evaluate clinicopathologic characteristics and survival impact associated with mismatch repair (MMR) deficient subgroups of endometrial cancer (EC) in patients undergoing universal screening for Lynch Syndrome. A retrospective cohort study using a prospectively maintained gynecologic oncology registry of patients who underwent surgery for EC was...
Hellman, Kristina Holmberg, Erik Bjurberg, Maria Borgfeldt, Christer Dahm-Kähler, Pernilla Flöter Rådestad, Angelique Hjerpe, Elisabet Högberg, Thomas Marcickiewicz, Janusz Rosenberg, Per
...
Published in
Gynecologic oncology
Vulvar cancer affects mainly elderly women and with an ageing population the incidence has increased. We explored the primary treatment patterns and relative survival of patients with vulvar squamous cell carcinoma (VSCC) by stage and age-group. A population-based nationwide study on women diagnosed with VSCC between 2012 and 2016 and registered in...
Bantie, Laychiluh Tadesse, Solomon Likisa, Jimma Yu, Mingfeng Noll, Benjamin Heinemann, Gary Lokman, Noor A Ricciardelli, Carmela Oehler, Martin K Beck, Andrew
...
Published in
Gynecologic oncology
Cyclin-dependent kinases 4 and 6 (CDK4/6) are fundamental drivers of the cell cycle and are involved in the initiation and progression of various cancers. Deregulation of the CDK4/6-cyclin D-retinoblastoma (Rb) pathway is common in ovarian cancer and is associated with an aggressive phenotype and poor prognosis. Patients with advanced ovarian cance...
Bogani, Giorgio DI Donato, Violante Sopracordevole, Francesco Ciavattini, Andrea Ghelardi, Alessandro Lopez, Salvatore Simoncini, Tommaso Plotti, Francesco Casarin, Jvan Serati, Maurizio
...
Published in
Gynecologic oncology
Conization aims to remove pre-neoplastic lesions of the uterine cervix. Several techniques for conization have been compared, but evidence regarding the most effective therapeutic option is scant. Here, we aimed to compare the recurrence rate following laser conization and loop electrosurgical excision procedure (LEEP) in patients with high-grade c...
Romero, Ignacio Rubio, M Jesús Medina, Manuel Matias-Guiu, Xavier Santacana, Maria Schoenenberger, Juan-Antonio Guerra, Eva Maria Cortés, Alfonso Minig, Lucas Coronado, Pluvio
...
Published in
Gynecologic oncology
Olaparib is a potent inhibitor of poly(ADP-ribose) polymerase (PARP)-1, 2, and 3 with potential activity in endometrial cancer (EC). In this window-of-opportunity trial, women with operable type 1 EC received olaparib oral tablets (300mg) twice daily for 28days before surgery. The primary objective was to evaluate the effects of olaparib on EC in t...
Riedinger, Courtney J Kimball, Kristopher J Kilgore, Larry C Bell, Clayton W Heidel, Robert E Boone, Jonathan D
Published in
Gynecologic oncology
As a protective response, during starvation organisms withdraw energy from growth and reproduction to focus on cellular maintenance. Cancer cells cannot undergo this differential response which has been theorized as an adjunct to improve both the effect of chemotherapy treatment and reduce treatment side effects. We sought to investigate the feasib...
Hall, M R Dehbi, H-M Banerjee, S Lord, R Clamp, A Ledermann, J A Nicum, S Lilleywhite, R Bowen, R Michael, A
...
Published in
Gynecologic oncology
We investigated the safety and efficacy of a combination of the oral tyrosine kinase inhibitor, nintedanib (BIBF 1120) with oral cyclophosphamide in patients with relapsed ovarian cancer. Patients with relapsed ovarian, fallopian tube or primary peritoneal cancer received oral cyclophosphamide (100 mg o.d.) and were randomised (1,1) to also have ei...
Hicks-Courant, Katherine Kanter, Genevieve P Giuntoli, Robert L 2nd Schapira, Marilyn M Bekelman, Justin E Latif, Nawar A Haggerty, Ashley F Morgan, Mark A Burger, Robert Ko, Emily M
...
Published in
Gynecologic oncology
To assess whether the number of practice sites per gynecologic oncologist (GO) and geographic access to GOs has changed over time. This is a retrospective repeated cross-sectional study using the 2015-2019 Physician Compare National File. All GOs in the 50 United States and Washington, DC, who had completed at least one year of practice were includ...
Chelariu-Raicu, Anca Nick, Alpa Urban, Renata Gordinier, Mary Leuschner, Carola Bavisotto, Linda Molin, Graziela Zibetti Dal Whisnant, John K Coleman, Robert L
Published in
Gynecologic oncology
This randomized open-label phase II study evaluated the safety and clinical activity of EP-100 plus weekly paclitaxel in patients with recurrent ovarian cancer expressing positive LHRH receptor. In a limited "run-in" dose escalation phase for EP-100, six patients were treated with ascending dose levels (13 mg/m2, 20 mg/m2, 30 mg/m2). In the randomi...
Fejzo, Marlena S Chen, Hsiao-Wang Anderson, Lee McDermott, Martina Sj Karlan, Beth Konecny, Gottfried E Slamon, Dennis J
Published in
Gynecologic oncology
There is an immunoreactive subtype of ovarian cancer with a favorable prognosis, but the majority of ovarian cancers have limited immune reactivity. The reason for this is poorly understood. This study aimed to approach this question by identifying prognostically relevant genes whose prognostic mRNA expression levels correlated with a genomic event...
